Search

Your search keyword '"O'Sullivan, M. Gerard"' showing total 365 results

Search Constraints

Start Over You searched for: Author "O'Sullivan, M. Gerard" Remove constraint Author: "O'Sullivan, M. Gerard"
365 results on '"O'Sullivan, M. Gerard"'

Search Results

1. Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma

2. FIGURE 5 from Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

3. FIGURE 2 from Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

4. Supplementary Figure S2 from Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

5. FIGURE 3 from Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

6. Supplementary Table S5 from Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

7. FIGURE 4 from Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

8. FIGURE 1 from Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

9. Data from Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion

10. A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma.

12. Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria

13. Oncolytic vesicular stomatitis virus is safe and provides a survival benefit for dogs with naturally occurring osteosarcoma

14. Supplemental Table S2 from Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor

15. Figure S2 from Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention

17. Supplementary Figure S3 from Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20

18. Data from Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor

20. Data from Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20

21. Supplementary Figures 1 - 5 from Kava Blocks 4-(Methylnitrosamino)-1-(3-pyridyl)-1-Butanone–Induced Lung Tumorigenesis in Association with Reducing O6-methylguanine DNA Adduct in A/J Mice

22. Supplementary figure legends from Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention

23. Supplementary Table 1 from Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention

24. Supplementary Tables 1 through 3, Supplementary Figure Legends, and Supplementary Materials and Methods from Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20

27. Supplemental Information from Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor

28. Figures S1 through S7 from Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor

29. Table S1 and S3 through S10 from Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor

31. Supplementary Figure 2 from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

32. Supplementary Figure 6 from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

33. Supplementary Figure 5 from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

34. Supplementary Figure 1 from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

35. Supplementary Figure 3 from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

36. Supplementary Figure Legend from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

37. Supplementary Figure 4 from An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

38. Supplementary Table 1 from Vaccination for Invasive Canine Meningioma Induces In Situ Production of Antibodies Capable of Antibody-Dependent Cell-Mediated Cytotoxicity

39. Supplementary Table 3 from Vaccination for Invasive Canine Meningioma Induces In Situ Production of Antibodies Capable of Antibody-Dependent Cell-Mediated Cytotoxicity

40. Data from Vaccination for Invasive Canine Meningioma Induces In Situ Production of Antibodies Capable of Antibody-Dependent Cell-Mediated Cytotoxicity

41. Supplementary Methods from Vaccination for Invasive Canine Meningioma Induces In Situ Production of Antibodies Capable of Antibody-Dependent Cell-Mediated Cytotoxicity

42. Supplementary Table 2 from Vaccination for Invasive Canine Meningioma Induces In Situ Production of Antibodies Capable of Antibody-Dependent Cell-Mediated Cytotoxicity

46. sj-pdf-1-vet-10.1177_03009858221100436 – Supplemental material for Meningioma with rhabdoid features: Pathologic findings in dogs

47. An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model

49. A Transposon-Based Genetic Screen in Mice Identifies Genes Altered in Colorectal Cancer

50. ssDNA nanotubes for selective targeting of glioblastoma and delivery of doxorubicin for enhanced survival

Catalog

Books, media, physical & digital resources